文献速递药物相互作用治疗药物监测与药物基因组学

利福平合用他克莫司治疗的优化挑战:病例系列

Challenges in optimizing tacrolimus therapy in patients treated with rifampin: A case series.
PubMed 文献 · Br J Clin Pharmacol · 2025-09-30

两例移植患者合用利福平时需将他克莫司剂量增至120 mg/日以维持治疗浓度,浓度剂量比低至0.11 μg/L/mg;停用利福平后7-15天内他克莫司水平延迟但显著升高,需大幅减量。提示利福平影响下他克莫司代谢变异极大,需每日治疗药物监测,应尽量避免联用。

要点

  • 利福平合用期间他克莫司剂量可需增至120 mg/日,浓度剂量比低至0.11 μg/L/mg
  • 停用利福平后7-15天内他克莫司水平延迟但显著升高,需大幅减量
  • 启动、持续和停用利福平时均需每日治疗药物监测,多学科协作,尽量避联用

核心结论

  • 利福平显著影响他克莫司药代动力学,导致代谢变异极大,需每日治疗药物监测。
  • 利福平与他克莫司联用应尽可能避免,需多学科协作管理。

研究设计与样本

  • 病例系列,报告两例移植患者合用利福平与他克莫司的药代动力学影响。

主要发现

  • 一例在利福平合用期间他克莫司剂量需增至120 mg/日以维持治疗浓度,浓度剂量比低至0.11 μg/L/mg。
  • 两例停用利福平后他克莫司水平延迟但显著升高,需在7-15天内大幅减量。

关键数值与推荐

  • 利福平合用期间他克莫司剂量需增至120 mg/日,浓度剂量比低至0.11 μg/L/mg。
  • 停用利福平后7-15天内他克莫司水平延迟但显著升高,需大幅减量。

临床怎么用

  • 启动、持续和停用利福平时应每日监测他克莫司浓度。
  • 尽可能避免他克莫司与利福平联用,需多学科协作管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tacrolimus is a cornerstone immunosuppressant in transplantation medicine with a narrow therapeutic window. Drug-drug interactions with strong CYP3A4 and P-glycoprotein modulators, such as rifampin and azole antifungals, significantly alter tacrolimus exposure and complicate therapy. Two transplant cases illustrates the impact of rifampin on tacrolimus pharmacokinetics. In one case, the tacrolimus dosage had to be increased to 120 mg/day during rifampin coadministration to maintain therapeutic concentrations, with a concentration-to-dose ratio (CDR) as low as 0.11 μg/L/mg. In both cases, cessation of rifampin led to a delayed but significant rise in tacrolimus levels, requiring substantial dose reductions within 7-15 days. These cases highlight the extreme variability in tacrolimus metabolism under the influence of rifampin and emphasize the need for daily therapeutic drug monitoring when starting, continuing and discontinuing rifampin. A multidisciplinary approach is essential and, when possible, the tacrolimus-rifampin combination should be avoided.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Houwen JPA, de Vries Schultink AHM, Peters BJM, et al. Challenges in optimizing tacrolimus therapy in patients treated with rifampin: A case series. Br J Clin Pharmacol. 2025. PMID: 41025974. doi:10.1002/bcp.70298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。